Demonstrates effective bacterial osteomyelitis treatment in rats using AI-engineered nanocrystals, suggesting new therapeutic possibilities.
Bacterial osteomyelitis remains a formidable challenge in clinic because existing monotherapies fail to block inevitable infection, uncontrolled inflammation, and impaired bone regeneration concurrently. Here, we present an AI-assisted strategy that integrates antibacterial, anti-inflammatory, and pro-osteogenic activities into a single nanocrystal. Through machine learning‑assisted screening from FDA-approved active pharmaceutical ingredients (API), we identified glycyrrhizic acid and simvastatin as a multifunctional combination capable of self-assembling into uniform nanocrystals (SGNCs) with ultrahigh drug loading. SGNCs effectively neutralize reactive oxygen species, suppress M1 macrophage polarization, promote bactericidal effects, and reverse infection-impaired osteogenic differentiation. Mechanistically, RNA sequencing analysis further reveals that the beneficial effects of SGNCs are associated with the inhibition of inflammatory response via cytokine-cytokine receptor interaction pathway and the activation of bone regeneration program via the Wnt signaling pathway. As a consequence, SGNCs eradicate bacterial burden and restore bone microarchitecture with excellent biocompatibility in a rat osteomyelitis model. Our insights highlight an AI-assisted strategy that creates a mechanism-targeting nanomedicine solely from APIs for the efficient treatment of bacterial osteomyelitis, which currently requires multimodal management.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: